AstraZeneca DEP® candidate advance triggers milestone to Starpharma

20 April 2017

Melbourne, Australia; 20 April 2017: Starpharma (ASX: SPL, OTCQX: SPHRY) announced the achievement of a key preclinical milestone for its DEP® drug delivery technology in combination with a proprietary oncology molecule from AstraZeneca. The advance triggers a US$2 million milestone payment under Starpharma’s multiproduct DEP® license. This is the final preclinical milestone prior to advancing the first AZ DEP® candidate to clinical trials and follows the completion of extensive testing and scale up activities.

Read more

© Starpharma Holdings Limited 2017